In this trial, ATLAS was used to identify neoantigens in each patient’s tumor, recognized by their CD4 and/or CD8 T cells, and the identified neoantigens were incorporated into a patient’s personalized vaccine in the form of SLPs. Here, CD8A is linked to neoplasm.